Logo image of JSPR

JASPER THERAPEUTICS INC (JSPR) Stock Fundamental Analysis

USA - NASDAQ:JSPR - US4718712023 - Common Stock

1.85 USD
+0.06 (+3.35%)
Last: 11/18/2025, 2:15:33 PM
Fundamental Rating

2

Overall JSPR gets a fundamental rating of 2 out of 10. We evaluated JSPR against 533 industry peers in the Biotechnology industry. JSPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. JSPR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

JSPR had negative earnings in the past year.
In the past year JSPR has reported a negative cash flow from operations.
In the past 5 years JSPR always reported negative net income.
JSPR had a negative operating cash flow in each of the past 5 years.
JSPR Yearly Net Income VS EBIT VS OCF VS FCFJSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -195.67%, JSPR is doing worse than 89.49% of the companies in the same industry.
JSPR's Return On Equity of -386.89% is on the low side compared to the rest of the industry. JSPR is outperformed by 74.48% of its industry peers.
Industry RankSector Rank
ROA -195.67%
ROE -386.89%
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
JSPR Yearly ROA, ROE, ROICJSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JSPR Yearly Profit, Operating, Gross MarginsJSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

JSPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for JSPR has been increased compared to 5 years ago.
There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JSPR Yearly Shares OutstandingJSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
JSPR Yearly Total Debt VS Total AssetsJSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.50, we must say that JSPR is in the distress zone and has some risk of bankruptcy.
JSPR's Altman-Z score of -13.50 is on the low side compared to the rest of the industry. JSPR is outperformed by 77.49% of its industry peers.
There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.5
ROIC/WACCN/A
WACCN/A
JSPR Yearly LT Debt VS Equity VS FCFJSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

JSPR has a Current Ratio of 2.10. This indicates that JSPR is financially healthy and has no problem in meeting its short term obligations.
JSPR has a worse Current ratio (2.10) than 73.92% of its industry peers.
A Quick Ratio of 2.10 indicates that JSPR has no problem at all paying its short term obligations.
JSPR has a worse Quick ratio (2.10) than 72.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.1
JSPR Yearly Current Assets VS Current LiabilitesJSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for JSPR have decreased strongly by -17.84% in the last year.
EPS 1Y (TTM)-17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

JSPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.42% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.13%
EPS Next 2Y17.63%
EPS Next 3Y15.38%
EPS Next 5Y11.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JSPR Yearly Revenue VS EstimatesJSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
JSPR Yearly EPS VS EstimatesJSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JSPR Price Earnings VS Forward Price EarningsJSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JSPR Per share dataJSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

JSPR's earnings are expected to grow with 15.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.63%
EPS Next 3Y15.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JSPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JASPER THERAPEUTICS INC

NASDAQ:JSPR (11/18/2025, 2:15:33 PM)

1.85

+0.06 (+3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners78.28%
Inst Owner Change42.93%
Ins Owners1.17%
Ins Owner Change0.64%
Market Cap51.60M
Revenue(TTM)N/A
Net Income(TTM)-90.92M
Analysts78.67
Price Target13.09 (607.57%)
Short Float %5.53%
Short Ratio3.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.96%
Min EPS beat(2)-28.61%
Max EPS beat(2)-5.32%
EPS beat(4)0
Avg EPS beat(4)-19.12%
Min EPS beat(4)-29.09%
Max EPS beat(4)-5.32%
EPS beat(8)3
Avg EPS beat(8)-4.79%
EPS beat(12)7
Avg EPS beat(12)-1.9%
EPS beat(16)9
Avg EPS beat(16)-42.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.58%
EPS NY rev (1m)5.23%
EPS NY rev (3m)-5.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-6.01
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -195.67%
ROE -386.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.1
Altman-Z -13.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.38%
EPS Next Y-4.13%
EPS Next 2Y17.63%
EPS Next 3Y15.38%
EPS Next 5Y11.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.33%
EBIT Next 3Y-25.25%
EBIT Next 5YN/A
FCF growth 1Y-59.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.1%
OCF growth 3YN/A
OCF growth 5YN/A

JASPER THERAPEUTICS INC / JSPR FAQ

What is the ChartMill fundamental rating of JASPER THERAPEUTICS INC (JSPR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to JSPR.


What is the valuation status for JSPR stock?

ChartMill assigns a valuation rating of 0 / 10 to JASPER THERAPEUTICS INC (JSPR). This can be considered as Overvalued.


What is the profitability of JSPR stock?

JASPER THERAPEUTICS INC (JSPR) has a profitability rating of 0 / 10.


What is the financial health of JASPER THERAPEUTICS INC (JSPR) stock?

The financial health rating of JASPER THERAPEUTICS INC (JSPR) is 5 / 10.